596 related articles for article (PubMed ID: 10700175)
1. A gene expression database for the molecular pharmacology of cancer.
Scherf U; Ross DT; Waltham M; Smith LH; Lee JK; Tanabe L; Kohn KW; Reinhold WC; Myers TG; Andrews DT; Scudiero DA; Eisen MB; Sausville EA; Pommier Y; Botstein D; Brown PO; Weinstein JN
Nat Genet; 2000 Mar; 24(3):236-44. PubMed ID: 10700175
[TBL] [Abstract][Full Text] [Related]
2. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
3. Relevant genomics of neurotensin receptor in cancer.
Elek J; Pinzon W; Park KH; Narayanan R
Anticancer Res; 2000; 20(1A):53-8. PubMed ID: 10769634
[TBL] [Abstract][Full Text] [Related]
4. National Oncology Forum: perspectives for the year 2000.
DeVita VT; Bleickardt EW
Cancer J; 2001; 7 Suppl 1():S2-13. PubMed ID: 11504281
[TBL] [Abstract][Full Text] [Related]
5. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
Yamori T
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S74-9. PubMed ID: 12819939
[TBL] [Abstract][Full Text] [Related]
6. DualChip microarray as a new tool in cancer research.
Gillet JP; de Longueville F; Remacle J
Expert Rev Mol Diagn; 2006 May; 6(3):295-306. PubMed ID: 16706734
[TBL] [Abstract][Full Text] [Related]
7. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
8. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
9. Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray.
Kim TM; Jeong HJ; Seo MY; Kim SC; Cho G; Park CH; Kim TS; Park KH; Chung HC; Rha SY
Clin Cancer Res; 2005 Jan; 11(1):79-86. PubMed ID: 15671531
[TBL] [Abstract][Full Text] [Related]
10. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
11. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.
De Angelis PM; Kravik KL; Tunheim SH; Haug T; Reichelt WH
Mol Cancer; 2004 Apr; 3():11. PubMed ID: 15109396
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
[TBL] [Abstract][Full Text] [Related]
13. From correlation to causality: microarrays, cancer, and cancer treatment.
O'Neill GM; Catchpoole DR; Golemis EA
Biotechniques; 2003 Mar; Suppl():64-71. PubMed ID: 12664688
[No Abstract] [Full Text] [Related]
14. Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Daoud SS; Munson PJ; Reinhold W; Young L; Prabhu VV; Yu Q; LaRose J; Kohn KW; Weinstein JN; Pommier Y
Cancer Res; 2003 Jun; 63(11):2782-93. PubMed ID: 12782583
[TBL] [Abstract][Full Text] [Related]
15. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping.
Reinhold WC; Kouros-Mehr H; Kohn KW; Maunakea AK; Lababidi S; Roschke A; Stover K; Alexander J; Pantazis P; Miller L; Liu E; Kirsch IR; Urasaki Y; Pommier Y; Weinstein JN
Cancer Res; 2003 Mar; 63(5):1000-11. PubMed ID: 12615715
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
17. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
18. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data.
Blower PE; Yang C; Fligner MA; Verducci JS; Yu L; Richman S; Weinstein JN
Pharmacogenomics J; 2002; 2(4):259-71. PubMed ID: 12196914
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer.
Jung JJ; Jeung HC; Chung HC; Lee JO; Kim TS; Kim YT; Noh SH; Rha SY
Genomics; 2009 Jan; 93(1):52-61. PubMed ID: 18804159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
